We are live on ! Find out more
PJP icon

Invesco Pharmaceuticals ETF

106 hedge funds and large institutions have $70.7M invested in Invesco Pharmaceuticals ETF in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 7

76% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 17

20% more capital invested

Capital invested by funds: $59M → $70.7M (+$11.7M)

14% more funds holding

Funds holding: 93106 (+13)

0.24% more ownership

Funds ownership: 22.23%22.48% (+0.24%)

Holders
106
Holders Change
+13
Holders Change %
+13.98%
% of All Funds
1.28%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
21
Increased
30
Reduced
17
Closed
7
Calls
Puts
Net Calls
Net Calls Change

PJP Hedge Fund Activity: Q4 2025 in Review

106 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Invesco Pharmaceuticals ETF (PJP) for Q4 2025, worth a combined $70.7M — up 20% from $59M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new PJP positions and 7 closed out — a net gain of 14 holders — while 30 added to existing stakes and 17 trimmed.

The largest buyer was Wells Fargo, adding an estimated $1.87M. The largest seller was Goldman Sachs, exiting entirely with an estimated $2.15M sold.

  • 106 institutional investors held Invesco Pharmaceuticals ETF (PJP) as of Q4 2025, up from 93 in Q3 2025.
  • Funds reported $70.7M of Invesco Pharmaceuticals ETF stock for Q4 2025, up 20% quarter-over-quarter.
  • 21 funds opened new Invesco Pharmaceuticals ETF positions in Q4 2025 and 7 closed out, a net change of +14 holders.
  • The largest Invesco Pharmaceuticals ETF buyer in Q4 2025 was Wells Fargo, an estimated $1.87M added.
  • The largest Invesco Pharmaceuticals ETF seller in Q4 2025 was Goldman Sachs, an estimated $2.15M sold.

Based on aggregated 13F filings for Q4 2025.